**NOMATEN ONLINE-SEMINAR**

[**https://www.gotomeet.me/NCBJmeetings/nomaten-seminar**](https://www.gotomeet.me/NCBJmeetings/nomaten-seminar)

Tuesday, MAY 9th 2023 13:00 CET

**Antibodies dedicated to in vitro diagnosis.**

Dr. Stéphanie SIMON

CEA / Institut des sciences du vivant Frédéric Joliot / DMTS (Medicines and Healthcare Technologies) / SPI (Pharmacology and immunoanalysis Unit)

**Abstract**:

Antibodies in the development of immunological tests for in vitro diagnosis. Application in the context of infectious diseases and biological warfare agents (antibiotic resistance, COVID, EBOLA, mad cow, monkey pox ...).

**Bio:**

Stéphanie Simon completed her PhD in the Laboratory of Molecular and Cellular Neurobiology at the Ecole Normale Supérieure de Paris under the supervision of Dr Jean Massoulié. Then she joined the French Atomic Energy Commission in 1999 for a post-doctoral position in the Pharmacology and Immunoanalysis Unit. During this post-doctoral fellowship, her research activities were divided between applied research (development and optimization of the rapid test for post-mortem diagnosis of transmissible spongiform encephalopathies (TSE) marketed by Bio-Rad) and more fundamental research. At the end of her post-doctoral fellowship, she was recruited as a researcher in the same unit (Laboratory for Immunoanalytical researches (LERI)). She continued to work for many years on prion diseases, then from 2008 on the fight against biological warfare agents (“B” of the CBRN risks). Since 2013, she has been managing the Laboratory for Immunoanalytical researches. In this context, as a researcher, she carries out research supervision activities (mainly in development of in vitro diagnostic tests in infectious diseases and CBRN fields). Between 2017 and 2022, she has coordinated the biology for fundamental research division at CEA of the CBRN inter-ministerial R&D program. Since 2022, she is heading the Pharmacology and Immunoanalysis Unit, which is composed of 5 laboratories and about 140 people and whose objectives are i) the development of therapeutic molecules in the fields of brain delivery and biological warfare agents, and ii) tools and methods in the fields of immuno- and molecular detection, clinical diagnosis, Omics and mass spectrometry for health and environment. She is author or co-author of 89 publications (H-index 24) and two patents.

